Literature DB >> 12366807

TLS-CHOP target gene DOL54 expression in liposarcomas and malignant fibrous histiocytomas.

Hideharu Domoto1, Taisuke Hosaka, Kosuke Oikawa, Tetsuya Ohbayashi, Tsuyoshi Ishida, Miki Izumi, Keiichi Iwaya, Junya Toguchida, Masahiko Kuroda, Kiyoshi Mukai.   

Abstract

Downstream of the gene for the liposarcoma-associated fusion oncoprotein 54 (DOL54) is a target gene of the myxoid liposarcoma and round cell liposarcoma (M-LPS/RC-LPS) oncogene, TLS/FUS-CHOP. The DOL54 gene product is closely associated with adipogenic differentiation. DOL54 overexpression resulted in tumorigenicity when Chinese Hamster Ovary (CHO) cells were injected subcutaneously into nude mice. The biological significance of DOL54 expression for human malignant soft tissue tumors, however, has not yet been investigated. We examined TLS-CHOP and DOL54 expression in M-LPS/RC-LPS, well-differentiated liposarcoma and malignant fibrous histiocytoma (MFH), a tumor whose cellular origin has not been determined. We observed DOL54 expression in 50% of M-LPS/RC-LPS cases (in which TLS-CHOP was also expressed) and 33% of MFH cases, suggesting that a portion of MFH lesions may either derive from adipocytic precursor cells or have the potential to undergo adipogenic differentiation. In this manner, M-LPS/RC-LPS and MFH lesions may share tumorigenic characteristics, resulting from the unscheduled expression of DOL54.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12366807     DOI: 10.1046/j.1440-1827.2002.01391.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  1 in total

1.  Variation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.

Authors:  Kayo Suzuki; Yoshito Matsui; Nobuyuki Hashimoto; Norifumi Naka; Nobuhito Araki; Tomoatsu Kimura; Hideki Yoshikawa; Takafumi Ueda
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.